Skip to main content

Lung and thoracic cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.


ARCHER 1050: Dacomitinib hits the OS target in advanced EGFR-mutated NSCLC

Patients with advanced non-small-cell cancer with activating EGFR mutations derive a significant overall survival benefit from first-line treatment with dacomitinib relative to gefitinib, the ARCHER 1050 trial shows.


Advanced NSCLC PFS gain with alectinib maintained with longer follow-up

Updated results from the phase III ALEX trial show that the progression-free survival benefit conferred by alectinib over crizotinib is maintained over time in treatment-naïve patients with anaplastic lymphoma kinase alteration-positive, advanced non-small-cell lung cancer.

View from the clinic

Explaining immunotherapy to our patients with non-small cell lung cancer

Explaining immunotherapy

Immunotherapy is changing practice in lung cancer, and with this, patient education. In this 'View from the clinic' article, Advisory Board member Beth Eaby-Sandy describes how she explains the new immunotherapy treatments to her patients. 

Expert opinion

Pembrolizumab-chemotherapy combination in non-small cell lung cancer

Pembrolizumab-carboplatin-pemetrexed for NSCLC

Two editorial articles provide differing opinions on using pembrolizumab with pemetrexed and platinum chemotherapy for non-small cell lung cancer. In the first article, Stephen Liu argues for embracing this new treatment option, while in the second, Sally Lau and Natasha Leighl argue for a little more caution.

14-06-2018 | Lung cancer | ASCO 2018 | Video

Expert commentary: Lung cancer highlights, including the KEYNOTE-042 and CCGA studies

ASCO expert David Graham comments on the plenary KEYNOTE-042 trial, putting the findings in context of other recent research, and highlights the initial report from the CCGA study that could pave the way for a novel lung cancer screening approach. (5:02)

08-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: An update from ASCO 2018 on targeted therapies in lung cancer

Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).

07-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: Lung cancer research from ASCO 2018

Watch this video to find out which studies reported at the ASCO Annual Meeting 2018 caught the interest of Advisory board member Lecia Sequist. She also talks about her own research presented at the conference (6:38).

Case reports and studies

12-04-2016 | Non-small cell lung cancer | Case study | Collection

Navigating the advanced NSCLC patient pathway: New markers and targets - An interactive case study

This is an interactive case study presented by Johan Vansteenkiste, based on a patient case discussed a Springer Healthcare independent symposium at the ELCC 2016.

The purpose of this interactive case study of is for participants to test their knowledge and clinical practices in the management of patients with NSCLC, and gain knowledge of emerging first-line and relapse treatment pathways.

Journal articles and book chapters

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

10-05-2018 | Non-small cell lung cancer | Article

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Leonardi GC et al. J Clin Oncol 2018; 36(19): 1905-1912. doi:10.1200/JCO.2017.77.0305

23-04-2018 | Non-small cell lung cancer | Article

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall

Leonetti A et al. Cancer Treat Rev 2018; 66: 82-94. doi:10.1016/j.ctrv.2018.04.006

16-04-2018 | Lung cancer | Article

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde PA et al. N Eng J Med 2018. doi:10.1056/NEJMoa1716078

16-04-2018 | Non-small cell lung cancer | Article

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Hellmann MD et al. N Eng J Med 2018. 10.1056/NEJMoa1801946

16-04-2018 | Pembrolizumab | Article

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Gandhi L et al. N Eng J Med 2018. 10.1056/NEJMoa1801005

10-04-2018 | Response criteria | Article

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour L et al. Lancet Oncol 2017; 18(3): e143–e152. doi:10.1016/S1470-2045(17)30074-8

04-04-2018 | Non-small cell lung cancer | Article

Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer

Skrzypski M, Jassem J. Cancer Treat Rev 2018; 66: 114-121. doi:10.1016/j.ctrv.2018.04.001


01-02-2017 | Cancer immunotherapy | Primer | Collection

The fundamentals of cancer immunotherapy

A introductory guide to cancer immunotherapy for non-specialists, focusing primarily on the mechanisms of immune checkpoint inhibition and the role of these agents in anticancer therapy.

08-08-2017 | Non-small cell lung cancer | At a glance | Article

At a glance: The KEYNOTE lung cancer trials

Overwhelmed by the sheer number of KEYNOTE trials? Cannot keep them straight in your head? Here is our quick guide to the KEYNOTE lung cancer trials.

19-10-2017 | Lung and thoracic tumors | Guideline | Article

Lung and thoracic cancers clinical guidelines

A comprehensive set of clinical practice guidelines for lung and thoracic cancer from a wide range of relevant organizations.

image credits